You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Foundayo ™ (orforglipron) tablet
0.8 mg / 2.5 mg / 5.5 mg / 9 mg / 14.5 mg / 17.2 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
Can Foundayo™ (orforglipron) be used in people with autoimmune disorders?
Orforglipron has not been studied in people with significant and active autoimmune disorders. Eli Lilly and Company cannot provide treatment recommendations on the use of orforglipron in people with these conditions.
See important safety information, including boxed warning, in the attached prescribing information.
Content Overview
- Exclusion Criteria in the Orforglipron Weight Management Clinical Trials
- Clinical Considerations
- Enclosed Prescribing Information
- References
Exclusion Criteria in the Orforglipron Weight Management Clinical Trials
No information is available on the use of orforglipron in patients with autoimmune abnormalities. Patients were excluded from the orforglipron studies if they had evidence of a significant, active autoimmune abnormality, such as lupus or rheumatoid arthritis, that, in the investigator's opinion, was likely to require concurrent treatment with systemic glucocorticoids during the study.1,2
Clinical Considerations
Eli Lilly and Company cannot provide treatment recommendations on the use of orforglipron in patients with a history of a significant and active autoimmune disorder. In formulating an assessment and approach, the health care practitioner may consider
- the information provided
- the patient’s prior medical history and concomitant medications, and
- other individual factors.
The health care practitioner should consider potential risks and benefits of treatment options and monitor appropriately.
Enclosed Prescribing Information
FOUNDAYO™ (orforglipron) tablets, for oral use, Lilly
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
- Wharton S, Aronne LJ, Stefanski A, et al; ATTAIN-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. https://doi.org/10.1056/NEJMoa2511774
- Horn DB, Ryan DH, Giljanovic Kis S, et al; ATTAIN-2 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025;406(10522):2927-2944. https://doi.org/10.1016/S0140-6736(25)02165-8.
Date of Last Review: April 08, 2026